Compass Therapeutics, Inc. (CMPX) Reports In-Line Q2 EPS
Tweet
Share
E-mailGet Alerts CMPX Hot Sheet
Join SI Premium – FREE
Compass Therapeutics, Inc. (NASDAQ: CMPX) reported Q2 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $850 million.
For earnings history and earnings-related data on Compass Therapeutics, Inc. (CMPX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kalshi in early talks for IPO - The Information
- Neotech Metals closes $3.08M private placement
- JPMorgan Upgrades Sika AG (SIKA:SW) (SKFOF) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
